UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 6, 2018

 

 

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

 

 

Delaware   001-33057   76-0837053

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

355 Alhambra Circle

Suite 1250

Coral Gables, Florida

  33134
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 8.01

Other Events.

On August 6, 2018, the Company issued a press release announcing the appointment of Jason James as Senior Vice President of Commercial Operations and Analytics, Jeff Del Carmen as Senior Vice President of Sales and Marketing, Kevin Rohrbach as Senior Director of Patient Engagement/Advocacy, and Maria Pandolfo as Senior Director of Patient Services. The Company also announced the addition of three Senior Medical Science Liaisons (MSLs) to its team, bringing the total of its MSLs to five. A copy of this press release is attached hereto as Exhibit 99.1.

On August 7, 2018, the Company issued a press release announcing its results of operations for the three and six months ended June 30, 2018 and providing a corporate update. A copy of this press release is attached hereto as Exhibit 99.2.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press release issued by the Company on August 6, 2018.
99.2    Press release issued by the Company on August 7, 2018 .

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Catalyst Pharmaceuticals, Inc.
By:  

/s/ Alicia Grande

  Alicia Grande
  Vice President, Treasurer and CFO

Dated: August 7, 2018

 

3

Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Catalyst Pharmaceuticals Charts.
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Catalyst Pharmaceuticals Charts.